TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25584730

Group type: EXPERIMENTAL
Intervention: Mindfulness inspired protocol delivered by an Android application for smartphones
Number of subjects: 56

Group type: COMPARATOR
Intervention: Listening to relaxing music
Number of subjects: 56

Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 56
Study: 22909998

Group type: EXPERIMENTAL
Intervention: 45 Gy plus capecitabine
Number of subjects: 565

Group type: COMPARATOR
Intervention: 50 Gy plus capecitabine and oxaliplatin
Number of subjects: 565
Study: 21920036

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 0
Study: 19878390

Group type: COMPARATOR
Intervention: Retin-OX+ lotion applied on one side of the face for 8 weeks
Number of subjects: 30
Study: 16306324

Group type: EXPERIMENTAL
Intervention: High-functioning ASD group
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study: 15201246

Group type: EXPERIMENTAL
Intervention: Spironolactone 12.5‐50 mg/24 hours for three months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 10914827

Group type: EXPERIMENTAL
Intervention: Abdomino‐Perineal Excision (APE)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Anterior Resection (AR)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 188

Group type: COMPARATOR
Intervention: Anterior Resection (AR) for lower third rectal tumours
Number of subjects: 188
Study: 9285271

Group type: EXPERIMENTAL
Intervention: Modified Stroop Test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-clinical control groups (restrained and unrestrained eaters)
Number of subjects: 0
Study: 8441104

Group type: EXPERIMENTAL
Intervention: Surfactant treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 3582710

Group type: EXPERIMENTAL
Intervention: Hexyl nicotinate lotion applied topically
Number of subjects: 10
Study: 30146421

Group type: EXPERIMENTAL
Intervention: 1 or more missed treatments in the 4 months before enrollment
Number of subjects: 8499

Group type: EXPERIMENTAL
Intervention: Countries with a 4-month missed treatment risk > 5%
Number of subjects: 8499

Group type: EXPERIMENTAL
Intervention: Missed treatments
Number of subjects: 8499
Study: 27634117

Group type: EXPERIMENTAL
Intervention: Complete left-sided reverse remodeling (above-median change in both LAV and LVESV)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Discordant reverse remodeling (above-median change in only LAV or LVESV)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Lesser reverse remodeling (below-median LAV and LVESV change)
Number of subjects: 533
Study: 24847524

Group type: EXPERIMENTAL
Intervention: rFVIII-FS (25 IU kg−1 three times per week for a median of 50.7 weeks)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: rFVIII-FS
Number of subjects: 68
Study: 23210700

Group type: EXPERIMENTAL
Intervention: Training to perform the fit check
Number of subjects: 84

Group type: COMPARATOR
Intervention: No training to perform the fit check
Number of subjects: 84
Study: 20364681

Group type: EXPERIMENTAL
Intervention: Nitrosorbid (NS) and hydrogen sulfide‐based balneotherapy (HSB) applied alone or in combination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of HSB and NS
Number of subjects: 0
Study: 17977877

Group type: EXPERIMENTAL
Intervention: US-guided renal biopsy in supine antero-lateral position (SALP)
Number of subjects: 110

Group type: COMPARATOR
Intervention: US-guided renal biopsy in prone position (PP)
Number of subjects: 110
Study: 15901766

Group type: EXPERIMENTAL
Intervention: Higher hemoglobin target (13.5 to 14.5 g/dl)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Lower hemoglobin target (9.5 to 11.5 g/dl)
Number of subjects: 596
Study: 11134208

Group type: EXPERIMENTAL
Intervention: Number of lymph nodes examined (quartiles)
Number of subjects: 1664
Study: 9665648

Group type: EXPERIMENTAL
Intervention: Probabilistic reasoning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deductive reasoning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Language comprehension task
Number of subjects: 0
Study: 8067231

Group type: EXPERIMENTAL
Intervention: 1 mg morphine (intraarticular injection)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (intraarticular injection)
Number of subjects: 80
Study: 3056245

Group type: EXPERIMENTAL
Intervention: Carumonam
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 54
Study: 29291728

Group type: EXPERIMENTAL
Intervention: Hope assessed using The Herth Hope Index (HHI) at 3, 6, and 12 months post-surgery
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Hope assessed using The Herth Hope Index (HHI)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Hope assessment
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Isolated valve surgery
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Divorced/widowed/single women
Number of subjects: 416
Study: 26868284

Group type: EXPERIMENTAL
Intervention: Intensive Repeated Mailings (IRM, n=622)
Number of subjects: 1874

Group type: EXPERIMENTAL
Intervention: Standard Repeated Mailings (SRM, n=614)
Number of subjects: 1874

Group type: COMPARATOR
Intervention: Traditional Self-Help (TSH, n=638)
Number of subjects: 1874
Study: 24044687

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (LcS) probiotic drink, given once daily for the duration of the antibiotic course and continued for 7 days thereafter.
Number of subjects: 164

Group type: COMPARATOR
Intervention: No probiotic (control group).
Number of subjects: 164
Study: 22289130

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Medication (Fluoxetine)
Number of subjects: 108
Study: 20053950

Group type: EXPERIMENTAL
Intervention: Treatment 1
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Treatment 2
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Treatment 3
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Treatment 4
Number of subjects: 74
Study: 18946893

Group type: EXPERIMENTAL
Intervention: Equity ownership by the investigator
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Per capita payments to the research institution
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: No disclosure
Number of subjects: 470
Study: 16023710

Group type: EXPERIMENTAL
Intervention: Lidcombe Program (LP) treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Demands and Capacities Model (DCM) treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 13677776

Group type: EXPERIMENTAL
Intervention: 3M Tegaderm transparent surgical dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gauze dressing
Number of subjects: 0
Study: 11103176

Group type: EXPERIMENTAL
Intervention: Incremental technique (2% sevoflurane, increased every four to six breaths by 2% increments, to 8%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-concentration technique (8% sevoflurane from the outset)
Number of subjects: 60
Study: 9082223

Group type: EXPERIMENTAL
Intervention: Intraperitoneal infusion of bupivacaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (physiologic solution)
Number of subjects: 100
Study: 1335400

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6707202

Group type: EXPERIMENTAL
Intervention: 1.5 g protein/kg ideal body weight
Number of subjects: 17

Group type: COMPARATOR
Intervention: 0.8 g protein/kg ideal body weight plus 0.7 g carbohydrate/kg ideal body weight
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 17
Study: 31299927

Group type: EXPERIMENTAL
Intervention: Whole-volume ROI
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Single-slice ROI
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Small solid-sample ROI
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Whole-volume ROI (cancerous nodules)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Single-slice ROI (cancerous nodules)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Small solid-sample ROI (cancerous nodules)
Number of subjects: 33
Study: 29355092

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (CaCO3)
Number of subjects: 9
Study: 26955678

Group type: EXPERIMENTAL
Intervention: Ultrasonic conductometric acupoint penetration of WZR
Number of subjects: 40

Group type: COMPARATOR
Intervention: WZR (oral administration)
Number of subjects: 40
Study: 24216031

Group type: EXPERIMENTAL
Intervention: Implementation intention formation
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Strong goal intention
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Complete implementation intentions
Number of subjects: 616

Group type: EXPERIMENTAL
Intervention: Strong goal intentions
Number of subjects: 616
Study: 22267464

Group type: EXPERIMENTAL
Intervention: PEG‐IFN (pegylated interferon-α2b) for 52 weeks
Number of subjects: 221
Study: 20650361

Group type: EXPERIMENTAL
Intervention: Drug/device therapies
Number of subjects: 69966

Group type: EXPERIMENTAL
Intervention: Mean increases in LVEF
Number of subjects: 69966

Group type: EXPERIMENTAL
Intervention: Mean decreases in EDV and ESV
Number of subjects: 69966
Study: 17505452

Group type: EXPERIMENTAL
Intervention: Laparoscopic lymphadenectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Abdominal lymphadenectomy
Number of subjects: 80
Study: 15842026

Group type: EXPERIMENTAL
Intervention: Depression care programme targeting GPs, patients, and systematic follow-up
Number of subjects: 211

Group type: COMPARATOR
Intervention: Systematic follow-up programme
Number of subjects: 211
Study: 11772264

Group type: EXPERIMENTAL
Intervention: Novel therapies and vaccines for meningococcal disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 9423996

Group type: EXPERIMENTAL
Intervention: 0.5% proparacaine (Ophthetic)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline placebo (control condition)
Number of subjects: 30
Study: 8488226

Group type: EXPERIMENTAL
Intervention: 5-session, time-limited therapy (n = 16)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Time-unlimited therapy (n = 15)
Number of subjects: 31
Study: 3125602

Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 100
Study: 2540757

Group type: EXPERIMENTAL
Intervention: Evening primrose oil rich in gammalinolenic acid (GLA)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Safflower oil (placebo)
Number of subjects: 19
Study: 30256537

Group type: EXPERIMENTAL
Intervention: Rolapitant at the highest safe dose (720 mg)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Rolapitant at presumed therapeutic dose (180 mg)
Number of subjects: 184
Study: 27186630

Group type: EXPERIMENTAL
Intervention: Lifestyle-based education for women and their husbands
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Lifestyle-based education for women only
Number of subjects: 189

Group type: COMPARATOR
Intervention: Routine care (Control group)
Number of subjects: 189
Study: 25312876

Group type: EXPERIMENTAL
Intervention: Action Schools! BC (AS! BC) intervention
Number of subjects: 500000
Study: 23937347

Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Services as usual (Control)
Number of subjects: 164
Study: 20177420

Group type: EXPERIMENTAL
Intervention: Irinotecan and 5-FU treatment in patients with ABCB1 3435 T/T genotype
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Irinotecan and 5-FU treatment in patients with UGT1A1(*)28/(*)28 genotype
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Patients with toxicity during the first two cycles of treatment
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Carriers of the ABCB1 1236T-2677T-3435T haplotype
Number of subjects: 140
Study: 19244090

Group type: EXPERIMENTAL
Intervention: Red wine (12.5%)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ethanol solution (12.5%)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Beer (5.6%)
Number of subjects: 72

Group type: COMPARATOR
Intervention: De‐alcoholized beverages
Number of subjects: 72

Group type: COMPARATOR
Intervention: Water
Number of subjects: 72
Study: 16516118

Group type: EXPERIMENTAL
Intervention: Handheld, battery-operated fiberoptic bronchoscope (FOB) alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of handheld FOB, misting, and end-tidal carbon dioxide concentration (ETCO2)
Number of subjects: 18

Group type: COMPARATOR
Intervention: End-tidal carbon dioxide concentration (ETCO2) alone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Misting alone
Number of subjects: 18
Study: 15580170

Group type: COMPARATOR
Intervention: HGF serum levels in patients with parathyroid adenoma and secondary hyperplasia (preoperative and postoperative)
Number of subjects: 24

Group type: COMPARATOR
Intervention: TGFbeta1 serum levels in parathyroid adenoma (preoperative and postoperative)
Number of subjects: 24

Group type: COMPARATOR
Intervention: TGFbeta1 serum levels in parathyroid secondary hyperplasia (postoperative)
Number of subjects: 24

Group type: COMPARATOR
Intervention: IGF-I serum levels among all investigated groups of patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Postoperative IGF-I serum levels in parathyroid secondary hyperplasia
Number of subjects: 24
Study: 11401628

Group type: EXPERIMENTAL
Intervention: Activity primary schools
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional primary schools
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: All categories (gender, geographical areas, type of pre-schools and primary schools)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Initial mean refraction
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Educational scores
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Gender differences in language scores
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Myopes vs non-myopes
Number of subjects: 128
Study: 9419927

Group type: EXPERIMENTAL
Intervention: Preventive health care strategies (not specified dosage or duration)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Annual screening interventions for early cancer detection
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) assessment
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Dietary adherence
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: CAPE testing for mental health assessment
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Preventive Medicine profile
Number of subjects: 123
Study: 8487046

Group type: EXPERIMENTAL
Intervention: 12 g/m2 MTX as a 4‐hour infusion (high-dose [HDM])
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 g/m2 as a 36‐hour infusion (intermediate-dose [IDM])
Number of subjects: 60
Study: 3320181

Group type: EXPERIMENTAL
Intervention: Insulin 10 U and glucagon 1 mg in 500 ml 5% glucose in water via a peripheral vein for 2-6 h three times every day for 3 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: 5% glucose in an identical fashion
Number of subjects: 66
Study: 29237275

Group type: EXPERIMENTAL
Intervention: Early autism spectrum disorder intervention in bilingual homes (n = 13)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Early autism spectrum disorder intervention in monolingual homes (n = 24)
Number of subjects: 37
Study: 27662296

Group type: EXPERIMENTAL
Intervention: Patients without dementia who developed delirium (n=16)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Patients with dementia (n=54)
Number of subjects: 129
Study: 25360840

Group type: EXPERIMENTAL
Intervention: Xinxuekang (XXK) capsules
Number of subjects: 576

Group type: COMPARATOR
Intervention: Compound Danshen (CDS) tablets
Number of subjects: 576
Study: 23379265

Group type: EXPERIMENTAL
Intervention: Telephone-based physical activity counseling intervention (n = 44); 12-week duration, including 1 in-person session, 7 telephone sessions, and 1 follow-up in-person session.
Number of subjects: 92

Group type: COMPARATOR
Intervention: Wait-list control group (n = 48)
Number of subjects: 92
Study: 22104015

Group type: EXPERIMENTAL
Intervention: Everolimus and octreotide combination therapy for 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Octreotide monotherapy
Number of subjects: 0
Study: 19751082

Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 84
Study: 16534006

Group type: EXPERIMENTAL
Intervention: NSAIDs (frequent use > or =22 d/mo)
Number of subjects: 70971

Group type: EXPERIMENTAL
Intervention: Acetaminophen (frequent use > or =22 d/mo)
Number of subjects: 70971

Group type: EXPERIMENTAL
Intervention: NSAIDs (high dose > or =15 tablets per week)
Number of subjects: 70971

Group type: EXPERIMENTAL
Intervention: Acetaminophen (high dose > or =15 tablets per week)
Number of subjects: 70971

Group type: EXPERIMENTAL
Intervention: NSAIDs (frequent use among current smokers)
Number of subjects: 70971

Group type: EXPERIMENTAL
Intervention: NSAIDs (frequent use among never smokers)
Number of subjects: 70971
Study: 15562840

Group type: EXPERIMENTAL
Intervention: Surgical closure
Number of subjects: 91

Group type: COMPARATOR
Intervention: Amplatzer device implantation
Number of subjects: 91
Study: 11569654

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (single dose)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 8978861

Group type: EXPERIMENTAL
Intervention: Direct observation of child performance
Number of subjects: 30

Group type: COMPARATOR
Intervention: Parental interview
Number of subjects: 30
Study: 8482993

Group type: EXPERIMENTAL
Intervention: 15 mg methylprednisolone acetate injected locally
Number of subjects: 32

Group type: COMPARATOR
Intervention: Saline solution (control group)
Number of subjects: 32
Study: 3616850

Group type: EXPERIMENTAL
Intervention: 1 g of erythromycin daily for a week
Number of subjects: 114

Group type: COMPARATOR
Intervention: 2 g of erythromycin daily for a week
Number of subjects: 114
Study: 31858502

Group type: EXPERIMENTAL
Intervention: Tochen's formula (weight in kg + 6 cm)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Nasal septum‐tragus length (NTL) + 1 cm
Number of subjects: 167
Study: 30897289

Group type: EXPERIMENTAL
Intervention: rs1998374 (protective effect)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: rs911887 (risk effect)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: rs2255326 (risk effect)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: haplotype T-A-C (rs1998374-rs2255326-rs911887)
Number of subjects: 396
Study: 28480799

Group type: EXPERIMENTAL
Intervention: Employed at 7 months postpartum
Number of subjects: 124

Group type: COMPARATOR
Intervention: Not employed at 7 months postpartum
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Full-time employment
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Part-time employment
Number of subjects: 124
Study: 25559877

Group type: EXPERIMENTAL
Intervention: Metacognitive executive function training
Number of subjects: 25

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 25
Study: 22703532

Group type: EXPERIMENTAL
Intervention: Fludrocortisone 50 μg orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydrocortisone 50 mg intravenously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fludrocortisone and Hydrocortisone (combined)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo for Fludrocortisone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo for Hydrocortisone
Number of subjects: 12
Study: 21656143

Group type: EXPERIMENTAL
Intervention: Multidisciplinary pulmonary rehabilitation program for 3 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 34
Study: 18094720

Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 143

Group type: COMPARATOR
Intervention: High-dose lipid formulation of amphotericin B (HD‐LPD/AMB)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Caspofungin plus HD‐LPD/AMB
Number of subjects: 143
Study: 16137898

Group type: EXPERIMENTAL
Intervention: VNUS
Number of subjects: 16

Group type: COMPARATOR
Intervention: RGS
Number of subjects: 16
Study: 12968233

Group type: EXPERIMENTAL
Intervention: Regional ischemic preconditioning (IP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study: 11027806

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and B vaccine (HAB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Concomitant hepatitis A and B vaccines (HAV + HBV)
Number of subjects: 80
Study: 8622062

Group type: EXPERIMENTAL
Intervention: BU/CY
Number of subjects: 14

Group type: COMPARATOR
Intervention: CY/TBI
Number of subjects: 14
Study: 1610421

Group type: EXPERIMENTAL
Intervention: Domiodol 60 mg t.i.d.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6369431

Group type: EXPERIMENTAL
Intervention: 1 mg morphine intrathecally (spinal group)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg body weight of morphine i.v. (i.V. group)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg body weight epidurally (PDA group)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intrathecal and epidural opiates
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: CSF morphine concentration 24 hrs after injection
Number of subjects: 29
Study: 30995657

Group type: EXPERIMENTAL
Intervention: F + V (fruits and vegetables)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: HCO3 (oral sodium bicarbonate)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 108
Study: 30291483

Group type: EXPERIMENTAL
Intervention: 400-μg misoprostol rectally with 5-IU oxytocin IV
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: 400-μg misoprostol sublingually with 5-IU oxytocin IV
Number of subjects: 636

Group type: COMPARATOR
Intervention: Placebo with 5-IU oxytocin IV
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Comparison between sublingual and rectal misoprostol
Number of subjects: 636